These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 2427833)

  • 1. The additional properties of beta adrenoceptor blocking drugs.
    Prichard BN; Tomlinson B
    J Cardiovasc Pharmacol; 1986; 8 Suppl 4():S1-15. PubMed ID: 2427833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic aspects of intrinsic sympathomimetic activity in beta-blocking drugs.
    Prichard BN
    Am J Cardiol; 1987 May; 59(13):13F-17F. PubMed ID: 2883871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future.
    Prichard BN
    Br J Clin Pharmacol; 1978 May; 5(5):379-99. PubMed ID: 26370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central hemodynamics of beta-adrenoceptor blocking drugs: beta 1 selectivity versus intrinsic sympathomimetic activity.
    Svendsen TL
    J Cardiovasc Pharmacol; 1983; 5 Suppl 1():S21-5. PubMed ID: 6188916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of beta-adrenoceptor blocking drugs possessing partial agonist activity, with special reference to pindolol.
    Aellig WH
    J Cardiovasc Pharmacol; 1983; 5 Suppl 1():S16-20. PubMed ID: 6188915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology of pindolol.
    Aellig WH
    Am Heart J; 1982 Aug; 104(2 Pt 2):346-56. PubMed ID: 6125094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrinsic sympathomimetic activity and coronary blood flow.
    Berdeaux A; Giudicelli JF
    Br J Clin Pharmacol; 1982; 13(Suppl 2):175S-180S. PubMed ID: 6125167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrinsic sympathomimetic activity: clinical fact or fiction?
    Taylor SH
    Am J Cardiol; 1983 Nov; 52(9):16D-26D. PubMed ID: 6139009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetamolol: cardiovascular effects of a new cardioselective beta-adrenoceptor blocker possessing partial agonistic activity and lacking membrane-stabilizing activity.
    Beaulieu G; Grimes D; Muirhead C; Oshiro G
    Can J Physiol Pharmacol; 1984 Jun; 62(6):610-6. PubMed ID: 6146394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of beta-blockade with beta-1-selectivity or intrinsic sympathomimetic activity on some cardiorespiratory responses to exercise.
    Yonga GO; Oyuga HW; Njeru EK
    East Afr Med J; 1993 Jul; 70(7):405-8. PubMed ID: 7904931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardioselective and nonselective beta-adrenoceptor blocking drugs in hypertension: a comparison of their effect on blood pressure during mental and physical activity.
    Floras JS; Hassan MO; Jones JV; Sleight P
    J Am Coll Cardiol; 1985 Jul; 6(1):186-95. PubMed ID: 2861218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)].
    Lemmer B
    Herz; 1982 Jun; 7(3):168-78. PubMed ID: 6124492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac effects of beta-adrenoceptor blockade with intrinsic sympathomimetic activity during submaximal exercise.
    Ades PA
    Br J Clin Pharmacol; 1987; 24 Suppl 1(Suppl 1):29S-33S. PubMed ID: 2894223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of combined alpha-beta-blockade. I.
    Louis WJ; McNeil JJ; Drummer OH
    Drugs; 1984; 28 Suppl 2():16-34. PubMed ID: 6151889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients.
    van den Meiracker AH; Man in't Veld AJ; Boomsma F; Fischberg DJ; Molinoff PB; Schalekamp MA
    Circulation; 1989 Oct; 80(4):903-14. PubMed ID: 2571431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of beta-adrenoceptor blockers under maximal exercise (pindolol v metoprolol v atenolol).
    Erikssen J; Thaulow E; Mundal R; Opstad P; Nitter-Hauge S
    Br J Clin Pharmacol; 1982; 13(Suppl 2):201S-209S. PubMed ID: 6125171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemodynamic consequences of intrinsic sympathomimetic activity in relation to changes in plasma renin activity and noradrenaline during beta-blocker therapy for hypertension.
    Man in't Veld AJ; Schalekamp MA
    Postgrad Med J; 1983; 59 Suppl 3(689):140-58. PubMed ID: 6139800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of beta 1-selectivity and intrinsic sympathomimetic activity in a beta-adrenergic blocking drug.
    Frishman WH
    Am J Cardiol; 1987 May; 59(13):33F-37F. PubMed ID: 2883876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma insulin levels and beta-adrenoceptor antagonists. The effects of cardioselective and non-cardioselective beta-adrenoceptor antagonists with and without intrinsic sympathomimetic activity on basal insulin level and insulin level after glucose stimulation in normoglycemic dogs.
    Conca W; Beck A; Bacher S; Raberger G
    Naunyn Schmiedebergs Arch Pharmacol; 1982 Jul; 320(1):63-6. PubMed ID: 6126816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade.
    McDevitt DG; Brown HC; Carruthers SG; Shanks RG
    Clin Pharmacol Ther; 1977 May; 21(5):556-66. PubMed ID: 15753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.